Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know how to set a trigger for a certain %, but I'm wondering about doing it over a set period of time. A trigger of 20% gains within 1 hour would not have yet triggered. My examples are purely hypothetical and not thought out or strategic - I'm just wondering if any knows how to set up an option like this?
Passion and perseverance in the face of a difficult task has been accredited as the key to success.
I'm certainly watching EKSO like a hawk, ready to invest on a moments notice if the stock starts climbing significantly.
Does anyone know about setting up specific option events? For example, if a stock climbs more than 15% in less than 24 hours as a trigger to initiating a buy or something along those lines. I'd be curious if anyone knows how to do this.
This should be big news for Ekso this summer: "Officially dubbed TALOS, the Iron Man program is an effort to provide better protection and situational awareness. Navy Lt. Cmdr. Allie Moon, deputy to the TALOS project’s chief engineer, said a prototype should be ready for demonstration sometime this summer. It will include a power supply, visual augmentation and a base layer that fits underneath the suit. The exoskeleton system, designed to help commandos with the heavy loads they must carry, should be ready some time next year, she said."
Source: http://www.tampabay.com/news/military/macdill/Students-flock-to-MacDill-to-see-innovation-in-action_166597281
Ekso is definitely one of my favorite companies. However, I'm not currently invested in EKSO and the accumulated deficit the company has is a getting a little scary compared to their revenue streams. Despite this deficit, amazingly the company doesn't have a lot of debt comparatively.
A home model exoskeleton, better stroke market penetration, industrial exoskeletons, and further military contracts could all turn this around very quickly. I'm of the impression that good progress is being made in each of these fields. Still, until the company turns the corner to make a profit it's risky. I'm probably not willing to be a shareholder until TALOS is demonstrated.
I emailed Conor and you are 100% correct. ReWalk is using technology originally created with DARPA funding. ReWalk has not however, been contracted by DARPA directly as far as I can tell.
abira, skepticone, stockholm dweller...
Thank you very much for the follow up, all of you.
Skeptic, you appear completely correct about the cables in the ReStore.
You also seem to have linked DARPA funding with their work with ReWalk, to which I stand corrected.
RKT (stockholm dweller) thank you for posting information from here on other boards. I myself was like you and simply watched these boards with out posting for a very long time. I look forward to seeing you post here more often.
Abira, I'm planning on contacting Conor Walch to see if he will definitively comment on the collaboration between ReWalk and DARPA. I wasn't aware of his exoskeleton involvement and I'm glad to learn about it. I was certainly overly confident in implying ReWalk's limited engagement in DARPA technology.
When I started posting on this board, I was often bringing information here without further follow up. I'm pleased to see that I'm becoming one of the minor players in terms of researching the field here.
Here's why the opposite might be true: Ekso Bionics having more overlap with Wyss than ReWalk. I'm certainly not a patent lawyer, but I do read a lot of the exoskeleton patents and watch a lot of what DARPA publishes.
Watch this video. The main speaker is the project manager of DARPA's Warrior Web program:
From an intellectual property standpoint, I believe it is reasonable to assume the two are completely unconnected until evidence can be shown otherwise. I'm not aware of any evidence that the Wyss Institute of Harvard has contributed anything they have learned or gained in their DARPA contract to assist or collaborate with ReWalk.
In fact, it is quite possible the Wyss Institute's DARPA agreement explicitly does not allow them to talk about, let alone use the technology they are developing for the D.O.D. in consumer products, like those they are working on with ReWalk.
If you look into the terms of government contracts you will find that the government has most of the authority and control over whether or not the party they contract can use a patent they are granted while working on their government contract, for commercial purposes. However, generally it is the government's goal to allow the companies to do so. See:
https://www.acquisition.gov/far/html/Subpart%2027_3.html
I'd appreciate correction if I'm wrong about any of this
China reveals military exoskeletons which are behind current US exoskeletons
https://www.nextbigfuture.com/2018/02/china-reveals-military-exoskeletons-which-are-behind-current-us-exoskeletons.html#so-post-comments-142530 (Scroll up after clicking)
A huge number of countries are working on this. It's unlikely they are all going down the wrong direction. Only a matter of time until Ekso succeeds in my opinion. No other U.S. exoskeleton company has ever received a DARPA contract as far as I know
Dr. Li received his Ph.D. in Applied Physics from Harvard University. I'm very glad to see him join the board.
As for Jack Peurach, I prefer his MS in Mechanical Engineering to Looby's BS in Chemical Engineering. It's a better degree and a better fit. They both have MBA's, but Peurach's is from a better school with better fits in specialization (Finance and Entrepreneurship).
On the other hand, Sun Power seems to be a pretty horrible failure. Although, it's not clear if it would have been possible for Peurach to fix the problems they had.
Overall, I would guess Puissance Capital better knows what's required for Ekso to achieve success in the stock market (largely a different thing than having success for their business as a whole). I think their apparent shake out of the company is going to be good for long term success.
Bionics will very likely replace wheelchairs, just not all at once. Currently Ekso Bionics uses a shared model, whereby hospital and rehab centers offer temporary rehabilitation sessions to distribute their costs to make it affordable per patient.
However, they are currently making a home model that will cost a lot less and also be much more advanced for providing continuous walking ability on a day to day level. I'm guessing it will have soft elements like tensile fabrics.
I think the meme I shared was overly simplistic and not telling the full story, but it's a meme - if you get complicated it won't be popular.
Acording to an Amazon company, 9gag has a global rank of 276. That is the 'traffic rank', compared to all other sites in the world. This meme reached the main page, the very first thing people saw for awhile. It's still within a short scrolling distance from the top. In 2015, TechCrunch said the site had 80 million monthly visitors.
https://www.alexa.com/siteinfo/9gag.com
Ekso Getting Social Media: https://9gag.com/gag/azXX37p?ref=w.upvotenoti
CRITICAL PATENT GETS PUBLISHED FOR EKSO:
https://patents.google.com/patent/EP3240518A1/en
Devices that purely seek to address metabolic cost will not significantly reduce joint pain or injuries. Load bearing devices that seek to reduce joint pain or injuries are too heavy to assist with metabolic cost. Full frame exoskeletons are too complex and heavy to be fieldable even if they could address these other issues.
Ekso's patent is making significant progress towards addressing these issues in a novel way.
----
Although not technically not finished with examination and not yet granted, this patent will curb research being done by many other companies. It would likely be foolish to spend money on R&D with a looming potential that any work done would be for naught if this patent gets granted.
There are phases with DARPA. First they get the technology they need at the research/component level. Then they integrate it. Then they test the integrated product. Then they transfer the large scale acquisition over to more major sections of the military.
notice this Press release:
"Ekso Bionics will engage Under Armour as a subcontractor in the third phase of the program to test the system’s durability and ability to be manufactured at scale, and support beta testing of the suit at the Army Research Laboratory Human Research and Engineering Directorate at the Aberdeen Proving Ground, Md."
My understanding is that Aberdeen Proving Ground is where things go post integration phase. I believe the fact things are moving forward and Ekso isn't announcing new DARPA research actually is a good sign, not a bad one. To me, it signals that acquisition might occur soon and that research might be largely completed.
If on the other hand, they weren't talking about "ability to manufactured at scale", and no further DARPA contracts were announced by now, I would be more worried their involvement didn't really lead anywhere. Luckily, this doesn't appear to be the case.
http://ir.eksobionics.com/press-releases/detail/566/ekso-bionics-selected-for-development-of-next-generation
Friedl et al. notes that “njuries associated with load carriage, although generally minor, can adversely affect an individual's mobility and thus reduce the effectiveness of an entire unit”. Exoskeleton designs that seek to minimize metabolic cost without assisting in reducing the load borne by a person will not address such injuries.
Ekso is fairly unique in that they are designing exoskeletons that reduce load through a 'web' of soft exoskeleton components.
See Ekso's work with DARPA:
http://ir.eksobionics.com/press-releases/detail/566/ekso-bionics-selected-for-development-of-next-generation
Breaking News on TALOS: http://www.nationaldefensemagazine.org/articles/2018/2/8/interview-with-socoms-new-acquisition-executive-james-smith
Pushed back a part of year on the Mk5 demonstration, but all signs sound very positive. If anything, it means Special Operations Command is willing to spend more time and money on the project than they originally intended. This is the exact opposite of a cut or cancellation to the program.
This is terrific news. The fact the exoskeleton technology is the limiting factor to their suit empowers ekso, proving it is the most cutting edge technology.
Angolds's linkedin has positive messages from current Ekso Employees. It doesn't seem like it was a falling out to me. Who knows what caused him to leave - it's possible he has an offer from a government agency.
It mostly depends who replaces him. If someone who worked at Boston Dynamics takes over - I'll be very excited. Plus with Ted Wang, I bet the board will be able to find someone very skilled.
I originally was very disappointed to see Nathan Harding leave, but actually I think the company started making much smarter moves after Looby came to run it. Looby is more qualified with more experience creating a successful companies.
I'm hoping the same will be true with Russ Angold leaving. Sometimes the original founders of a company are too close to have proper vision for the product.
Ekso has DARPA contracts. The DARPA invented the internet, gps, the GUI, google maps, siri, unix, the cloud, handheld radiation detectors - and more.
Expect big things to come from Ekso Bionics's collaboration with DARPA
Elon Musk: "When you have new technology, it takes time to make it lower cost and mass market. If you think of the early days of cell phones or laptops or any new technology - it starts off expensive"
Ekso is going to be huge - it just takes some time for the price to drop to become mass marketable
DARPA Robotics Challenge is ran by the same person who is running WarriorWeb, the project Ekso has been contracted on twice now (Task A & Task B). His name is Christopher Orlowski.
According to LinkedIn he's now working as an Acquisition Officer at the Army Rapid Capabilities Office. I would certainly say that not only is this a promotion, but it suggests to me that his DARPA research has turned into something the Army wants to acquire.
Cheers to Ekso Bionics, the company I love.
Military Exoskeleton Market to Grow at 26.12 % CAGR Worldwide- Trends, Emerging Growth Factors and Forecasts 2023
http://www.austriantribune.com/informationen/12939-military-exoskeleton-market-grow-2612-cagr-worldwide-trends-emerging-growth
Cybathlon is totally irrelevant for EKSO.
Being able to walk quickly DOES NOT MAKE A SIGNIFICANT DIFFERENCE at this stage in rehabilitation for exoskeletons.
Rehabilitation and ambulation are largely separate goals.
What does matter to Ekso is how much their patients gaits improve after getting out of the exoskeleton. The primary factor determining this has to do with how much user imput there is. Ekso's SmartAssist blows the competition out of the water in this regard. The second major factor is going to be Functional Electronic Stimulation (FES). Another place Ekso has a big lead on almost all other exoskeletons.
Remember an Ekso paired with FES resulted in this:
newsroom.ucla.edu/releases/completely-paralyzed-man-voluntarily-moves-his-legs-ucla-scientists-report
To be fair, simply having an exoskeleton do most of the work, reading where the person wants to go, and doing it quickly is of some value. It's just not what Ekso's products are designed to do currently. When ambulation does come to be a primary goal of Ekso, I expect them to enter the Cybathlon
FORTIS seems to be making progress, remember Ekso has licensed technology to this. http://nationalinterest.org/blog/the-buzz/the-army-could-soon-have-super-soldiers-thanks-exoskeletons-23799
I'm not at all worried about any potential lawsuit. Ekso seems to be running their business faithfully in my eyes, although details would be appreciated.
I think institutions take a day or two to even read press releases that aren't critical, let alone determine their response.
I predict we'll see green the next few days.
I think the FDA reclassification will help EKSO. Short term I can see why you would think it would hurt by making it easier for competitors to compete with the GT, but I don't think that's the whole picture.
Ekso has multiple suits under development that might benefit from these changes.
Additionally, in terms of safety - I think the cream rises to the top. If a suit gets approved where people get injured, they won't last long just given market interaction.
Just a thought.
FES means upselling to current owners of the GT = higher profits for EKSO
If FES cures paralysis, doesn't matter how old it is.
I know parker hannifin suit, indego, is supposed to be FES compatable too, but I don't think it's actively in use with FES
Essentially, the SEC doesn't say it's inaccurate - just that the practices in play might mean that it could be.
"Simply put, a material weakness is one or more control deficiencies that create a reasonable possibility of a material misstatement in your company's annual or interim financial statements. This does not necessarily mean that a material misstatement has occurred, but only that the controls might not be good enough to detect or prevent a material misstatement on a timely basis."
https://www.sec.gov/info/smallbus/404guide/evaluation3.shtml
So it's totally unclear and I'd like to know what the material weakness is/was. I'll write IR and see what they say.
I'd like to say the FES news is more substantial, but I've never ran into this in any other stock I'm following so I couldn't say
REMEMBER THIS IN RELATION TO FES: http://newsroom.ucla.edu/releases/completely-paralyzed-man-voluntarily-moves-his-legs-ucla-scientists-report
Ted Wang will bring us above $5 is my gamble. I'm not even thinking of selling until at least the end of august 2018 as per TALOS
INTERVIEW W/ ERGONOMICS DECISION MAKER AT FORD: